Metadon Abcur (Methadone Hydrochloride)

Methadone is an opioid agonist used in the treatment of opioid dependence and chronic pain.

• Opioid dependence treatment: Stabilizes patients on a long‑acting opioid to reduce cravings and prevent withdrawal.
• Chronic pain management: Provides sustained analgesia for patients with severe, persistent pain unresponsive to other opioids.
• Opioid withdrawal mitigation: Alleviates withdrawal symptoms during detoxification protocols.

• Methadone acts as a full agonist at the mu‑opioid receptor, binding with high affinity and activating the receptor to inhibit nociceptive neurotransmission. This activation reduces neuronal excitability and diminishes the perception of pain while also suppressing the physiological response to opioid withdrawal, thereby stabilizing opioid‑dependent individuals.

Methadone may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: mild to moderate upset stomach.
• Constipation: reduced bowel motility.
• Dizziness: sensation of light‑headedness.
• Sweating: increased perspiration, especially at dose adjustments.

Serious or Rare Side Effects

• Respiratory depression: slowed breathing that can be life‑threatening.
• QT interval prolongation: cardiac rhythm disturbance that may lead to arrhythmia.
• Severe hypotension: marked drop in blood pressure causing faintness or shock.

When prescribing methadone, several safety considerations are essential.

• Assess cardiac risk: obtain a baseline ECG due to potential QT prolongation.
• Monitor respiratory status: watch for depression, especially after dose changes.
• Avoid use in severe hepatic impairment: impaired metabolism may increase drug levels.
• Use caution in pregnancy: discuss potential risks with an obstetric specialist.
• Store at ambient temperature: keep in the original container, protect from moisture and light.

Methadone interacts with several medication classes; awareness helps prevent adverse events.

Major Interactions (Avoid)

• Concomitant CNS depressants (e.g., benzodiazepines): increased risk of respiratory depression.
• QT‑prolonging agents (e.g., macrolide antibiotics): additive cardiac risk.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise methadone plasma concentrations.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin): may reduce methadone efficacy.
• Anticholinergics: may worsen constipation.
• Selective serotonin reuptake inhibitors: potential for serotonin syndrome when combined.